Effect of Vitamin D deficiency treatment on thyroid function and autoimmunity markers in Hashimoto’s thyroiditis: A double?blind randomized placebo?controlled clinical trial

Abstract

Background: Te link between autoimmune thyroid diseases and Vitamin D defciency has been reported. However, there are controversies in this  regard. We conducted a double?blind randomized placebo?controlled  clinical trial to investigate the e?ect of Vitamin D defciency treatment on  thyroid function and autoimmunity marker (thyroid peroxidase antibody  [TPO?Ab]) in patients with Hashimoto’s thyroiditis. Materials and Methods: ifty?six patients with Hashimoto’s thyroiditis and Vitamin D defciency (25?hydroxyvitamin D level ?20 ng/mL) were randomly allocated into two groups to receive Vitamin D (50000 IU/week, orally) or placebo  for 12 weeks, as Vitamin D?treated (n = 30) and control (n = 26) groups,  respectively. TPO?Ab, thyroid?stimulating hormone (TSH), parathormone, calcium, albumin, and creatinine concentrations were compared before  and after trial between and within groups. Te data were presented as  mean (standard error [SE]) and analyzed by appropriate tests. Results: Mean (SE) of Vitamin D was increased in Vitamin D?treated group (45.5  [1.8] ng/mL vs. 12.7 [0.7] ng/mL, P = 0.01). Mean (SE) of TPO?Ab did not signifcantly change in both groups (734 [102.93] IU/mL vs. 820.25 [98.92] IU/mL, P = 0.14 in Vitamin D?treated and 750.03 [108.7] [IU/mL] vs. 838.07 [99.4] [IU/mL] in placebo?treated group, P = 0.15). Mean (SE) of TSH was not changed in both groups after trial, P = 0.4 and P = 0.15 for Vitamin D?treated and control groups, respectively. No signifcant  di?erence was observed between two study groups in none studied  variables (P > 0.05). Conclusion: Vitamin D treatment in Vitamin D  defcient patients with Hashimoto’s thyroiditis could not have signifcant  e?ect on thyroid function and autoimmunity.